olverembatinib
ascentage pharmaceuticals
['olverembatinib', '#gi']
the first dataset of #olverembatinib (#hqp1351) in patients with #gist demonstrates therapeutic potential with a clinical benefit rate of 83.3% 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.